FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C.	20549	

STATEMENT		ANGESIN	JENE	ICIAI	OWNED	
SIAIEMENI	ог сп	ANGES II	A DEIJEL	ICIAL	OWNERS	חור

OMB APPROVAL									
OMB Number: 3235-0287									
Estimated average burden									
hours per response:	0.5								

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person* Cox John				2. Issuer Name and Ticker or Trading Symbol <u>Dyne Therapeutics, Inc.</u> [DYN]						(Che	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner				
(Last)	,	irst) PEUTICS, INC	(Middle)		3. Date of Earliest Transaction (Month/Day/Year) 03/25/2024					,	Officer (below)	give title See Re	below)	specify	
1560 TRAPELO ROAD			4	4. If Amendment, Date of Original Filed (Month/Day/Year)				Line	6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person						
(Street) WALTHA	AM M	ÍΑ	02451									_	•	than One Repo	
(City)	(S	tate)	(Zip)	[Rule 10b5-1(c) Transaction Indication Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.										
		Та	ble I - Non-	-Derivati	ve Se	curities	s Ac	quired, D	isposed (of, or Be	neficially	Owned			
Date			2. Transacti Date (Month/Day	Execution Date,		Code (Instr.			5. Amoun Securities Beneficia Owned Fo	s Form (D) or ollowing (I) (In	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)			
						Code	Amount	(A) or (D) Price		Transacti	ransaction(s) nstr. 3 and 4)		(,		
			Table II - D (€					uired, Dis s, options				Owned			
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	action (Instr.	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficially Owned Following Reported Transactio	Ownershi Form: y Direct (D) or Indirec (I) (Instr. 4	Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		(Instr. 4)	11(5)	
Stock Option (Right to Buy)	\$26.06	03/25/2024		A		679,853		(1)	03/24/2034	Common Stock	679,853	\$0	679,853	B D	

Explanation of Responses:

1. This option was granted on March 25, 2024. The shares underlying the option are scheduled to vest over four years, with 25% of the shares vesting on March 25, 2025, and the remainder vesting in equal monthly installments thereafter, subject to continuous service

Remarks:

Chief Executive Officer and President

/s/ Richard Scalzo, Attorney-in-03/27/2024

Fact

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.